Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer

Debora Landi1, Federica Gemignani, Alessio Naccarati

  • 1Dipartimento di Biologia, University of Pisa, Via Derna, 1, 56126 Pisa, Italy.

Carcinogenesis
|January 15, 2008
PubMed

Insights

Common genetic variations in micro-RNA (miRNA) binding sites may influence cancer risk. This study found specific miRNA-binding site polymorphisms in CD86 and INSR genes are associated with increased colorectal cancer risk.

Area of Science:

  • Genetics
  • Molecular Biology
  • Oncology

Background:

  • Micro-RNAs (miRNAs) are small non-coding RNAs that regulate gene expression by binding to messenger RNAs.
  • Genetic polymorphisms within miRNA-binding sites on 3' untranslated regions (UTRs) could alter miRNA regulation.
  • Gene deregulation is a key factor in cancer development.

Purpose of the Study:

  • To investigate the role of common polymorphisms in miRNA-binding sites within 3' UTRs of cancer-associated genes in colorectal cancer (CRC) risk.
  • To identify specific single-nucleotide polymorphisms (SNPs) that affect miRNA binding and are associated with CRC.

Main Methods:

  • Bioinformatic algorithms (PicTar, DianaMicroT, miRBase, miRanda, TargetScan, microInspector) were used to identify miRNA-binding sites in 104 candidate CRC genes.
  • Fifty-seven SNPs were identified within these binding sites and analyzed for their impact on miRNA binding affinity using Gibbs free energy variation.
  • Case-control association studies were conducted on a Czech population, known for high CRC incidence, to evaluate the association of common polymorphisms with CRC risk.

Main Results:

  • Eight common polymorphisms were selected for further investigation.
  • Statistically significant associations were found between CRC risk and variant alleles of CD86 (OR = 2.74) and INSR (OR = 1.94) genes in homozygous variant carriers.
  • These findings represent the first report of a positive association between miRNA-binding site SNPs and cancer risk.

Conclusions:

  • Common polymorphisms within miRNA-binding sites can influence individual cancer risk.
  • Specific SNPs in CD86 and INSR genes are associated with an increased risk of colorectal cancer.
  • This study highlights the potential of miRNA-binding site polymorphisms as biomarkers for cancer risk assessment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...